| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 5 | +20.00% | +1.24% | +0.99% | +0.26% | +0.55% | — |
| 14d | 5 | +20.00% | +0.61% | +0.44% | +0.17% | +1.77% | — |
| 30d | 5 | +60.00% | +0.92% | -1.50% | +2.42% | +1.02% | — |
| 60d | 5 | +60.00% | +1.18% | +3.88% | -2.70% | -7.76% | — |
| 90d | 5 | +60.00% | +2.63% | +7.25% | -4.61% | -14.63% | — |
| 180d | 5(3 pending) | +0.00% | +27.31% | +7.91% | +19.40% | +19.40% | — |
| 1y | 5(5 pending) | — | — | — | — | — | — |
| 2y | 5(5 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 25,255 | — | — | 0 | May 1, 2026 | May 4, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 11,002 | $229.85 | $2.53M | 24,911 | May 1, 2026 | May 4, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 25,255 | — | — | 35,913 | May 1, 2026 | May 4, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 29,927 | — | — | 59,854 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 21,721 | $157.92 | $3.43M | 34,662 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 21,721 | $243.00 | $5.28M | 12,941 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 29,927 | $243.00 | $7.27M | 12,941 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 2,283 | $243.00 | $554.8K | 10,658 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 21,721 | — | — | 21,721 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 29,927 | $156.15 | $4.67M | 42,868 | Feb 17, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 1,847 | — | — | 13,469 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 1,847 | — | — | 3,692 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 3,546 | — | — | 3,546 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 1,349 | — | — | 12,007 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 49,382 | — | — | 49,382 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 385 | $243.45 | $93.7K | 11,622 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 1,349 | — | — | 1,349 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 528 | $243.45 | $128.5K | 12,941 | Feb 15, 2026 | Feb 18, 2026 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 21,721 | $192.71 | $4.19M | 10,658 | Oct 17, 2025 | Oct 20, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 21,721 | $157.92 | $3.43M | 43,442 | Oct 17, 2025 | Oct 20, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 21,721 | $157.92 | $3.43M | 32,379 | Oct 17, 2025 | Oct 20, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 19,137 | $163.55 | $3.13M | 10,658 | Jul 17, 2025 | Jul 18, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 25,255 | — | — | 25,255 | May 1, 2025 | May 5, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 25,255 | — | — | 40,797 | May 1, 2025 | May 5, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 11,002 | $156.31 | $1.72M | 29,795 | May 1, 2025 | May 5, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 385 | $156.15 | $60.1K | 15,542 | Feb 18, 2025 | Feb 18, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 1,350 | — | — | 2,698 | Feb 15, 2025 | Feb 18, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 1,350 | — | — | 15,927 | Feb 15, 2025 | Feb 18, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 5,539 | — | — | 5,539 | Feb 15, 2025 | Feb 19, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 89,781 | — | — | 89,781 | Feb 15, 2025 | Feb 19, 2025 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 10,984 | $144.59 | $1.59M | 11,577 | May 1, 2024 | May 3, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 22,255 | — | — | 53,510 | May 1, 2024 | May 3, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 22,255 | — | — | 22,561 | May 1, 2024 | May 3, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 25,255 | — | — | 50,510 | May 1, 2024 | Oct 31, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | SALE EVP, Innovative Medicine, R&D | 10,984 | $144.59 | $1.59M | 14,577 | May 1, 2024 | Oct 31, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASE EVP, Innovative Medicine, R&D | 25,255 | — | — | 25,561 | May 1, 2024 | Oct 31, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 65,163 | — | — | 65,163 | Feb 15, 2024 | Feb 20, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 4,048 | — | — | 4,048 | Feb 15, 2024 | Feb 20, 2024 ↗ | View → |
| JNJ JOHNSON & JOHNSON | PURCHASEGRANT Stock grant | 75,765 | — | — | 75,765 | May 1, 2023 | May 2, 2023 ↗ | View → |